New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
04:55 EDTBIOD, BIOD, BIOD, BIOD, BIOD, LXRX, LXRX, LXRX, LXRX, LXRX, ISIS, ISIS, ISIS, ISIS, ISIS, LLY, LLY, LLY, LLY, LLYAmerican Diabetes Association to hold scientific sessions
74th Scientific Sessions of the ADA to be held in San Francisco on June 13-17.
News For BIOD;LXRX;ISIS;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 3, 2015
08:04 EDTLLYDenovo Biopharma licensed Pomaglumetad Methionil from Eli Lilly
Subscribe for More Information
07:16 EDTLLYCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 3 at 8 am; not all company presentations may be webcasted. Webcast Link
March 2, 2015
10:00 EDTISISOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:53 EDTLLYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
08:22 EDTISISIsis Pharmaceuticals downgraded at Stifel
Subscribe for More Information
08:06 EDTISISIsis Pharmaceuticals downgraded to Hold from Buy at Stifel
Subscribe for More Information
07:20 EDTLXRXCowen to hold a conference
Subscribe for More Information
07:04 EDTISISIsis Pharmaceuticals earns $15M from GlaxoSmithKline for advancing ISIS-TTR Rx
Isis Pharmaceuticals (ISIS) announced that it has earned a $15M milestone payment from GSK (GSK) related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
February 27, 2015
09:43 EDTISISIsis Pharmaceuticals sees reporting data on eight or more drugs in FY15
Sees initiating up to 13 studies, broadening pipeline with up to five new drugs in partnered, unpartnered programs.
09:38 EDTISISIsis Pharmaceuticals sees FY15 pro forma NOL in mid-$50M range
Sees ending FY15 with more than $630M in cash, representing net cash outflows of only $100M to move forward its pipeline.
09:34 EDTISISIsis Pharmaceuticals reports Q4 EPS 25c, consensus 2c
Subscribe for More Information
February 26, 2015
15:30 EDTISISNotable companies reporting before tomorrow's open
Subscribe for More Information
February 24, 2015
10:48 EDTISISIsis says ISIS-PKKRx reduced prekallikrein levels in Phase 1 study
Isis Pharmaceuticals announced results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95% in prekallikrein, or PKK, Isis said. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema. ISIS-PKKRx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg up to 400 mg for the multiple doses. After three weeks of dosing, subjects in the 100, 200, 300 and 400 mg multiple-dose cohorts displayed a mean reduction of PKK of 33, 69, 87 and 92%, respectively, from baseline. In this study, ISIS-PKKRx was generally well tolerated.
06:34 EDTLLYEli Lilly CEO states company is not for sale, Financial Times says
Subscribe for More Information
February 23, 2015
16:34 EDTLXRXLexicon Chief Scientific Officer resigns
Lexicon Pharmaceuticals announced the resignation of Brian Zambrowicz, Ph.D., executive vice president and Chief Scientific Officer, to pursue another opportunity. Dr. Zambrowicz will be assisting in shifting his responsibilities to other members of the company in order to ensure a seamless transition. In connection with the change, Lexicon will merge its discovery and clinical functions and conduct an immediate search for a head of research and development. Dr. Zambrowicz has agreed to be available to provide consulting services as the company completes this transition.
08:31 EDTLLYEli Lilly announces delay in submission of basal insulin peglispro beyond Q1
Subscribe for More Information
07:22 EDTISISSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
07:06 EDTLLYEli Lilly and Incyte announces positive results for baricitinib
Subscribe for More Information
February 20, 2015
15:20 EDTISISIsis Pharmaceuticals management to meet with JPMorgan
Subscribe for More Information
February 19, 2015
08:04 EDTLLYEli Lilly extends Evacetrapib Phase 3 trial by six months
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use